vimarsana.com

Page 15 - புனே சீரம் நிறுவனம் ஆஃப் இந்தியா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Year-end cheer: India closer to Covid-19 vaccine after UK s Oxford nod - india news

Year-end cheer: India closer to Covid-19 vaccine after UK s Oxford nod - india news
hindustantimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hindustantimes.com Daily Mail and Mail on Sunday newspapers.

Towards an effective vaccination distribution policy

Towards an effective vaccination distribution policy Updated: Updated: December 28, 2020 00:48 IST The government must examine the principle underlying the triage scheme and whether private players should be allowed space Share Article AAA A vendor waits for customers at his roadside eatery stall in front of a mural representing a frontline COVID-19 warrior painted on a wall in New Delhi on December 27, 2020.   | Photo Credit: AFP The government must examine the principle underlying the triage scheme and whether private players should be allowed space India plans to vaccinate 300 million people against COVID-19 over the next 6-7 months. The government plans to give priority to healthcare workers and other front-line workers, followed by everyone who is above 50 years of age. This will mean that roughly 20% of the population will be vaccinated by July or August 2021.

Bharat Biotech halfway through in one of country s largest phase-3 trials

Hyderabad-based Bharat Biotech, one of the three vaccine candidates to have applied for emergency use authorisation, has recruited half the number of volunteers it needs for phase-3 human clinical trials of Covaxin. The company, along with Pune’s Serum Institute of India, had been asked to provide additional safety and efficacy data of its phase-3 trials by the drug regulator after the first presentation was made to the subject expert committee. V K Paul, member-health Niti Aayog and head of national expert group on vaccines said that Pfizer has not yet submitted its data to the subject expert committee. He said, “New data has been given by at least one company and it is being examined.Process is sacrosanct. Let us see where it takes us.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.